Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 21, 2014; 20(15): 4276-4287
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4276
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4276
Advances in epigenetic biomarker research in colorectal cancer
Xi Wang, Ye-Ye Kuang, Xiao-Tong Hu, Biomedical Research Center, Sir Run Run Shaw Hospital, Zhejiang University and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou 310016, Zhejiang Province, China
Author contributions: Wang X and Kuang YY drafted the manuscript; Hu XT approved the final version for publication.
Supported by National Natural Science Foundation of China, No. 81071651 and No. 81372622; the Program for Zhejiang Leading Team of ST innovation, No. 2012R10046-03; Major State Basic Research Development Program, No. 2010CB834303; National High Technology Research and Development Program of China, No. 2012AA02A601; Major Projects in Zhejiang Province, No. 2012C13014-1; and the Fundamental Research Funds for the Central Universities, No. 2012FZA7020
Correspondence to: Xiao-Tong Hu, MD, PhD, Biomedical Research Center, Sir Run Run Shaw Hospital, Zhejiang University and Key Laboratory of Biotherapy of Zhejiang Province, Qing Chun East Road 3, Hangzhou 310016, Zhejiang Province, China. hxt_hangzhou@sina.com
Telephone: +86-571-86006363 Fax: +86-571-86006363
Received: September 23, 2013
Revised: November 5, 2013
Accepted: January 14, 2014
Published online: April 21, 2014
Processing time: 205 Days and 14.3 Hours
Revised: November 5, 2013
Accepted: January 14, 2014
Published online: April 21, 2014
Processing time: 205 Days and 14.3 Hours
Core Tip
Core tip: Epigenetic biomarkers, including DNA methylation, microRNA expression and histone modification, may have the potential for the screening, diagnosis, prognosis and recurrence surveillance in colorectal cancer patients.